Abcuro
Abcuro is a clinical-stage biotechnology company developing first-in-class anti-KLRG1 monoclonal antibody immunotherapies (lead asset ulviprubart/ABC008) to selectively deplete highly cytotoxic T cells for treating rare autoimmune diseases and cancers, primarily inclusion body myositis (IBM).
- Company typePrivate
- Founded2020
- HeadquartersNewton, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Abcuro does
Abcuro is a clinical-stage biotechnology company headquartered in Newton, Massachusetts, developing first-in-class monoclonal antibody immunotherapies that target killer cell lectin-like receptor G1 (KLRG1) to selectively deplete highly cytotoxic T cells while sparing regulatory and central memory T cells. The company's lead asset, ulviprubart (ABC008), is an anti-KLRG1 monoclonal antibody in late-stage clinical development for inclusion body myositis (IBM), a rare, debilitating, and progressive autoimmune muscle disease with no approved treatments. Beyond IBM, Abcuro is developing ulviprubart in T cell large granular lymphocytic leukemia (T-LGLL) — a Phase 1/2 trial with interim data presented at ASH 2025 — and in T and NK cell lymphomas. The company also has a preclinical anti-KLRG1 blocking antibody, ABC015, being developed for oncology applications including multiple myeloma, with support from the Multiple Myeloma Research Foundation.
The underlying platform rests on the biological insight that KLRG1 is highly expressed on late-differentiated effector memory and effector T cells (TEM/TEMRA) that drive tissue damage in autoimmune disease and certain cancers. Abcuro's approach of selectively depleting these cytotoxic T cells while preserving protective immune populations represents a mechanistically differentiated therapeutic strategy. The company has secured FDA and EMA Orphan Drug Designations plus FDA Fast Track Designation for ulviprubart in IBM, and the Phase 2/3 MUSCLE registrational trial enrolled 272 patients across 30+ global sites, with topline results reported in February 2026 showing a missed primary endpoint in the overall population but 50% slowing of disease progression in a pre-specified mild-to-moderate subgroup.
Abcuro is a pre-revenue, venture-backed private company that has raised approximately $397 million across multiple financing rounds (Series A-1 of $42M in 2021, Series B of $155M in 2023, Series C of $200M in 2025). Its business model is traditional pharmaceutical product sales contingent on regulatory approval, supported by a sales-led go-to-market approach that engages clinical investigators and physicians through medical conferences (AAN, ASH, GCOM, EULAR) and peer-reviewed publications. The customer base is composed of rare disease patients across approximately 75,000 IBM patients in the US, EU, and Japan combined, plus T-LGLL and lymphoma populations. Recent commercial leadership additions (CCO in June 2025, CFO in August 2025) indicate active preparation for potential market launch.
Abcuro firmographics
Firmographics- Name
- Abcuro
- Legal name
- Abcuro, Inc.
- Website
- https://abcuro.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Abcuro is a clinical-stage biotechnology company developing first-in-class anti-KLRG1 monoclonal antibody immunotherapies (lead asset ulviprubart/ABC008) to selectively deplete highly cytotoxic T cells for treating rare autoimmune diseases and cancers, primarily inclusion body myositis (IBM).
- Ownership category
- akta.pro rank
Abcuro industry classification
Industry- Product category
- Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA)
- akta.pro secondary industries
- Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Rare Immunology, Autoimmune & Autoinflammatory Therapies (HLAIAIAE)
Keywords
Where Abcuro is headquartered
LocationHeadquarters
- HQ city
- Newton
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Abcuro business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Pharmaceutical Product Revenue: Pre-revenue clinical stage biotechnology company. Expected to generate revenue through potential future sales of ulviprubart (ABC008) if approved for commercial sale. Revenue model would be traditional pharmaceutical product sales.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels5 records
Abcuro product offering
Product offeringCore offering
Abcuro develops first-in-class monoclonal antibody immunotherapies targeting KLRG1 to selectively deplete highly cytotoxic T cells implicated in autoimmune diseases and cancer. The lead product, ulviprubart (ABC008), is in late-stage clinical development for inclusion body myositis (IBM), with ongoing trials in T cell large granular lymphocytic leukemia (T-LGLL) and T/NK cell lymphomas. A second pipeline program, ABC015, is an anti-KLRG1 blocking antibody in preclinical development for oncology indications.
Product overview
Abcuro is a clinical-stage biotechnology company developing first-in-class immunotherapies targeting KLRG1 to selectively modulate highly cytotoxic T cells implicated in autoimmune diseases and cancer. The company's lead product is ulviprubart (ABC008), an anti-KLRG1 monoclonal antibody in late-stage clinical development for inclusion body myositis (IBM), with ongoing Phase 1/2 trials in T cell large granular lymphocytic leukemia (T-LGLL). The company is also developing ABC015, an anti-KLRG1 blocking antibody for oncology applications. Abcuro's approach focuses on selectively targeting and depleting well-differentiated cytotoxic KLRG1+ T cells while sparing naïve, regulatory, and central memory T cells to maintain normal immune homeostasis.
Differentiator
Problem solved
Functional benefit
Products and services
- Ulviprubart (ABC008) First-in-class anti-KLRG1 monoclonal antibody that selectively depletes highly cytotoxic T cells while sparing regulatory and central memory T cells. In late-stage clinical development for inclusion body myositis (IBM), with additional trials ongoing in T cell large granular lymphocytic leukemia (T-LGLL) and T/NK cell lymphomas.
- ABC015
Quantifiable outcome
- 50% slowing of disease progression relative to placebo in pre-specified subgroup of patients with mild to moderate IBM (baseline IBMFRS ≥29)
- +3 more outcomes
Companies that use Abcuro
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles2 records
Abcuro technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Abcuro partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- ImaginAbstrategicNon-exclusive license agreement for ImaginAb's CD8 ImmunoPET imaging agent to image T cell infiltration in skeletal muscle in IBM patients. Proprietary technology provides whole-body PET imaging of CD8+ T cells.
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
Abcuro competitors and assessment
Company assessmentDirect peers
- argenx: argenx is a clinical-stage and now commercial immunology biotech developing first-in-class antibody therapeutics (efgartigimod/Vyvgart) for rare autoimmune diseases. Most directly comparable to Abcuro given shared focus on mAb modality, rare autoimmune indications, and similar European-anchored development strategy.
- AnaptysBio: AnaptysBio is a clinical-stage biotechnology company developing therapeutic antibodies for autoimmune and inflammatory diseases, including PD-1 agonists and IL-36R antagonists. Comparable to Abcuro as a focused mAb developer in immunology with similar company stage.
- Kezar Life Sciences: Kezar Life Sciences is a clinical-stage biotech developing novel small molecule and protein therapeutics for autoimmune diseases (lupus nephritis, etc.). Comparable to Abcuro given similar clinical stage, autoimmune focus, and rare disease positioning.
Emerging players
- Caballeta Bio: Cabaletta Bio is a clinical-stage biotech developing engineered T cell therapies (CAR-T) for autoimmune diseases. Comparable as a focused autoimmune company at similar development stage with a novel mechanism targeting pathogenic immune cells.
- Kymera Therapeutics: Kymera Therapeutics is a clinical-stage biotech developing targeted protein degradation (PROTAC) therapies for immunology and oncology indications. Comparable given similar clinical-stage profile and autoimmune/immune-driven disease focus.
- Immunic Therapeutics: Immunic Therapeutics is a clinical-stage biotech developing oral small molecules for chronic inflammatory and autoimmune diseases (multiple sclerosis, ulcerative colitis). Comparable given similar clinical-stage profile and autoimmune disease focus.
Broad incumbents
- Horizon Therapeutics (Amgen): Horizon Therapeutics (acquired by Amgen in 2023) was a leading rare autoimmune disease company with multiple approved products (Tepezza, Krystexxa). Comparable to Abcuro as the established commercial leader in the rare autoimmune space Abcuro aims to enter with ulviprubart.
- MorphoSys: MorphoSys (acquired by Novartis in 2024) was a clinical-stage and commercial mAb company developing therapeutics for cancer and autoimmune diseases (Monjuvi). Comparable to Abcuro in mAb development focus and therapeutic area overlap.
- ChemoCentryx (Amgen): ChemoCentryx (acquired by Amgen in 2022) developed small molecule therapeutics for rare inflammatory/autoimmune diseases (Tavneos). Comparable to Abcuro as a rare autoimmune disease-focused biotech that achieved commercial success in a niche indication.
Others
- Roivant Sciences: Roivant Sciences is a healthcare platform company that develops and commercializes late-stage therapeutic candidates across multiple disease areas. Comparable as an adjacent rare disease-focused platform that could acquire or partner with Abcuro.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Abcuro social profiles
Digital presenceAbcuro compliance and trust
Trust signalCompliance3 records
Abcuro financial estimates
Financial estimateRevenue estimate
Valuation estimate
Abcuro leadership team
Management profileNumber of profiles
Profiles10 records
Abcuro funding detail
Funding detailFunding overview
Funding rounds8 records
Investors23 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Abcuro M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Abcuro
What does Abcuro do?
Abcuro develops first-in-class monoclonal antibody immunotherapies targeting KLRG1 to selectively deplete highly cytotoxic T cells implicated in autoimmune diseases and cancer. The lead product, ulviprubart (ABC008), is in late-stage clinical development for inclusion body myositis (IBM), with ongoing trials in T cell large granular lymphocytic leukemia (T-LGLL) and T/NK cell lymphomas. A second pipeline program, ABC015, is an anti-KLRG1 blocking antibody in preclinical development for oncology indications.
Is Abcuro a public or private company?
Abcuro is a private company. It is classified as venture growth investor backed and is currently operating.
When was Abcuro founded?
Abcuro was founded in 2020. It employs 11 to 50 people.
Where is Abcuro based?
Abcuro is headquartered in Newton, United States, in the North America region.
How does Abcuro make money?
One revenue line is on record: pharmaceutical Product Revenue.
Who are Abcuro's main competitors?
Direct peers on record are argenx, AnaptysBio and Kezar Life Sciences. Emerging players are Caballeta Bio, Kymera Therapeutics and Immunic Therapeutics. Broad incumbents are Horizon Therapeutics (Amgen), MorphoSys and ChemoCentryx (Amgen). Roivant Sciences is listed as an others.
Does Abcuro have an API?
No public API is recorded for Abcuro.
What industry is Abcuro in?
Abcuro's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAA, Monoclonal Antibody Therapeutics (mAbs), with a secondary code of HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.